General Information of Drug (ID: DR1918)
Drug Name
Cladribine
Synonyms
Chlorodeoxyadenosine; Cladarabine; Cladaribine; Cladribine; CldAdo; Leustat; Leustatin; Mylinax; RWJ 26251; RWJ-26251; (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol; 2-CdA; 2-Chloro-2'-deoxy-beta-adenosine; 2-Chloro-2'-deoxyadenosine; 2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine; 2-Chlorodeoxyadenosine; 2CdA; 2ClAdo; 4291-63-8; 47M74X9YT5; ADENOSINE, 2-CHLORO-2'-DEOXY-; BRN 0624220; CHEBI:567361; Litak; MFCD00153939; MLS000028377; NSC 105014; NSC 105014-F; SMR000058553; UNII-47M74X9YT5
Indication Multiple myeloma [ICD11: 2A83] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 285.69 Topological Polar Surface Area 119
Heavy Atom Count 19 Rotatable Bond Count 2
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
20279
PubChem SID
610461 ; 855756 ; 866156 ; 7848433 ; 7978577 ; 7978957 ; 8165006 ; 14799875 ; 14897807 ; 26719669 ; 26757803 ; 29287787 ; 46386544 ; 46504588 ; 48415788 ; 49865077 ; 49903916 ; 49903918 ; 50104045 ; 50446026 ; 56312468 ; 56312469 ; 56312470 ; 56312853 ; 56422184 ; 57309572 ; 57330593 ; 71821359 ; 87323981 ; 92308638 ; 92713835 ; 99218181 ; 99431527 ; 99437023 ; 103602769 ; 104350170 ; 118046705 ; 124659094 ; 124757075 ; 124800053 ; 124886798 ; 124886799 ; 125163879 ; 126624559 ; 126655830 ; 128966217 ; 131314655 ; 134337856 ; 134984314 ; 135683425
ChEBI ID
CHEBI:567361
CAS Number
4291-63-8
TTD Drug ID
D05GJW
Formula
C10H12ClN5O3
Canonical SMILES
C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
InChI
1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey
PTOAARAWEBMLNO-KVQBGUIXSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
2-chloro-2'-deoxyadenosine-5'-triphosphate DM006060
452857
Unclear 1 [3]
2-chlorodeoxyinosine DM006058
136025223
Unclear 1 [2]
2-Chlorohypoxanthine DM006059
135421792
Unclear 2 [2]
Glucuronide conjugates of 2-CdA DM006061 N. A. Unclear 2 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006524 Cladribine 2-chlorodeoxyinosine Unclear ADA [2]
MR006526 Cladribine 2-chloro-2'-deoxyadenosine-5'-triphosphate Unclear DCK [3]
MR006527 Cladribine Glucuronide conjugates of 2-CdA Unclear Unclear [2]
MR006525 2-chlorodeoxyinosine 2-Chlorohypoxanthine Unclear Unclear [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Adenosine aminohydrolase (ADA) DME0060 Homo sapiens
ADA_HUMAN
3.5.4.4
[2]
Deoxycytidine kinase (DCK) DME0443 Homo sapiens
DCK_HUMAN
2.7.1.74
[3]
References
1 Cladribine was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human
3 Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.